Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells

Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial–mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Grueso, María José, González, Raúl, Muntané, Jordi, Bárcena, José Antonio, Padilla, C. Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826379/
https://www.ncbi.nlm.nih.gov/pubmed/31652503
http://dx.doi.org/10.3390/antiox8100501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826379/
https://www.ncbi.nlm.nih.gov/pubmed/31652503
http://dx.doi.org/10.3390/antiox8100501

Ejemplares similares